Coivas review

Coivas: a simple starting bill, with a price lock tied to the plan

Coivas is built around two compounded injections, semaglutide and tirzepatide, rather than a sprawling treatment menu. Its homepage advertises the first from $119 a month and the second from $199, with no membership fee. The practical attraction is a bill that bundles medication, delivery and ongoing support. The question we would settle before joining is what the starting figure buys for your prescribed treatment, and whether changing that treatment changes the bill.

Read the price lock carefully

The FAQ says your price is locked while you remain on the same medication and treatment plan. That is more specific than a general promise of no price hikes, but it does not define every change that might create a new plan. Ask whether clinician-directed titration remains inside your quote, what happens when you switch molecules, and whether canceling and returning loses the original rate. Get the answers alongside the amount you authorize rather than relying on a memory of the homepage.

The program describes one price covering the prescription, medication and support, with discreet delivery. There is no public dose-by-dose ladder. That leaves less homework than a separate membership plus a separate drug bill, but it still requires a personal quote. If affordability is the deciding factor, compare the same medication, dose and supply duration against the cheapest GLP-1 programs. Starting semaglutide and maintenance tirzepatide are not interchangeable budget items.

The clinician is named; your pharmacy is not

Coivas names Beluga Health as its clinical provider. It describes pharmacy fulfillment through licensed compounding pharmacies and outsourcing facilities, with the actual dispenser varying by location, medication and availability. We would ask for that pharmacy's name before an order is processed. A description of the network is useful, but the address on your prescription label is what lets you know who prepared your particular supply.

The site states that compounded medications are not FDA-approved. It also links its weight-loss advertising to a branded tirzepatide trial and describes the study population in the footnote. Those results should not be mistaken for an independently audited success rate for Coivas patients. We would give the clinical arrangements and refill support more weight than a weight-loss estimate slider. Your own response cannot be promised by an average printed in an advertisement.

Enrollment and transferring care

The company describes a short questionnaire, provider review, prescribing if appropriate and pharmacy shipping. It estimates that many prescriptions are written within a day and medication often arrives in one to three business days. Those are its estimates, not a delivery result we tested. Leave time for medical questions, documentation and pharmacy processing if you are trying to avoid a gap between refills.

Its transfer FAQ says an existing patient supplies proof of her current prescription for clinician review. Continuing the same dose remains conditional on clinical appropriateness. That is the right distinction to keep in mind: transferring is a new clinician's decision, not simply buying the next vial. Ask who handles a change in formulation or concentration, how follow-ups work, and what contact you have if the new prescription is different from the old one.

Canceling is about shipment timing

Coivas says to cancel before the upcoming medication shipment is processed; otherwise the cancellation applies to the following cycle. Its return policy says shipped medication generally cannot be returned, with remedies for confirmed errors or quality defects. It also discusses duplicate charges and consultations that did not occur. We would save the cancellation confirmation and ask when the pharmacy receives the next order, rather than assuming the visible billing date is the last chance to act.

The homepage promotes a weight-loss guarantee, but the separate return policy mainly explains dispensing errors and billing exceptions. Before relying on the broader guarantee, ask for its exact eligibility requirements and measurement period. If nursing, pregnancy planning or tolerability could interrupt treatment, ask whether those circumstances qualify. A stop in care should not leave you discovering the financial terms after another shipment has already been processed.

Our take for mothers

Coivas may suit someone who wants an inclusive monthly bill and portal access to a clinician without a separate membership. It claims all 50 states, but publishes little specifically about postpartum or breastfeeding care. We would discuss those issues before enrollment and confirm the actual pharmacy, ongoing quote and shipment cutoff together. Its straightforward presentation is useful only when those details remain straightforward after you choose your treatment. See our postpartum guide for the timing questions to bring.